Directly from the USA: Genetically Adjusted PSA Levels Improve Prediction of Prostate Cancer

Accounting for genetic determinants of constitutive, noncancer-related prostate-specific antigen (PSA) variation improves prediction of prostate cancer, according to a study published online June 1 in Nature Medicine.

Linda Kachuri, Ph.D., M.P.H., from the University of California in San Francisco, and colleagues conducted a multiancestry meta-analysis of 95,768 men and developed a PSA polygenic score (PGSPSA) to account for constitutive PSA variation.

Source: Advances and More licensed by HealthDay